Introduction
Glioblastoma multiforme is the most common form of brain tumor occurring in adults. This devastating disease is usually incurable and patients have a mean survival time of approximately 1 year after diagnosis. The highly invasive nature of glioblastoma makes surgical resection non-curative, and it has also been proposed that invading cells may be more resistant to radiation and chemotherapy (Giese et al., 2003) . Glioblastoma cells invade as single cells; these cells travel along white matter tracts and also along blood vessel walls and through the subpial glial space, with some cells traveling long distances. These cells do not generally invade through blood vessel walls or bone, and glioblastomas only very rarely metastasize outside the brain. This is distinct from the invasive behavior of cancer that has metastasized to the brain from other sites (Bellail et al., 2004) . These metastases are generally more delineated from surrounding tissue, invade short distances (often as groups of cells) and invade through blood vessel walls and bone.
Two common genetic changes that have been identified in glioblastoma are mutation of PTEN and the amplification and mutation of the gene for the epidermal growth factor receptor (EGFR; Ohgaki and Kleihues, 2007) . Both of these mutations have been linked to increased motility and invasion because of their aberrant activation of the phosphoinositide 3-kinase (PI3K) pathway (Tamura et al., 1999; Cai et al., 2005) . The PI3K pathway activates multiple downstream kinases including protein kinase C type i (PKCi), a member of the atypical protein kinase C family (Akimoto et al., 1996) . PKCi activation involves phosphorylation by PDK1 and binding to a Cdc42 family protein (Kanzaki et al., 2004) . The potential importance of PKCi as a downstream mediator in the PI3K pathway has been emphasized by the recent finding that it can itself function as an oncogene in both lung and ovarian cancers (Eder et al., 2005; Regala et al., 2005b) . Previous studies have shown that the atypical PKCs have a role in cell motility (Xu and Deng, 2006) ; however, it is not known whether they have a role specifically in glioblastoma cell motility, and the downstream events involved in atypical PKC-mediated motility have not been determined.
To assess the role of PKCi in glioblastoma, we previously performed a microarray analysis of gene expression in human glioblastoma cells depleted of PKCi by RNA interference (RNAi) (Baldwin et al., 2006) . This identified a number of candidate genes that are potentially regulated by PKCi. One of these was the small GTPase RhoB, a member of the Rho GTPase family of proteins, that regulates a variety of cellular processes including actin organization, proliferation and differentiation (Wheeler and Ridley, 2004) . RhoB has been shown to exhibit tumor repressive activity (Huang and Prendergast, 2006) . In human brain tumors, RhoB protein expression decreases with the increasing tumor grade (Forget et al., 2002) , suggesting that RhoB repression may have a role in increasing the aggressiveness of this cancer.
In this study, we describe a role for PKCi in glioblastoma cell motility and invasion. We show that PKCi negatively regulates the expression of RhoB, and that restoration of RhoB expression inhibits glioblastoma cell motility. We also show that RhoB is able to inhibit PKCi activity; the two proteins therefore are mutually antagonistic and may function as a switch for cell motility.
Results

PKCi depletion inhibits glioblastoma motility and invasion
The ability of glioblastoma cells to invade into normal surrounding tissue is influenced by their motility as well as ability to penetrate through tissue barriers such as extracellular matrix. To assess the role of PKCi in glioblastoma cell motility, we used 'scratch-wound' assays together with RNAi to reduce PKCi protein levels. We have previously shown that RNAi effectively reduces PKCi mRNA and protein levels by 75-90% without affecting mRNA levels of other PKC family members (Baldwin et al., 2006) . These assays showed that U87MG cells depleted of PKCi with two different RNA duplexes did not fill in a scratch as rapidly as cells treated with a control RNA duplex, suggesting decreased cell motility ( Figure 1a and Supplementary Figure S1A ). However, a caveat with these assays is that PKCi depletion slows the growth of glioblastoma cells; this gives rise to significant differences in cell densities over the 4-day period in which these assays are carried out, and some of the differences seen may be a consequence of this, rather than reflecting true effects on motility.
To overcome this problem, we also assessed glioblastoma cell motility using Transwell chambers. In these assays, control cells and cells depleted of PKCi are replated into Transwell chambers at the same density and 24 h later the numbers of cells that have crossed the chamber membrane are counted. The effects of PKCi depletion on cell number were not significant at 24 h (data not shown). Depletion of PKCi in U87MG cells using siPKCiA and siPKCiB resulted in 37 and 46% decreases, respectively, in the number of cells that crossed the chamber membrane, indicating a true decrease in motility (Figures 1b and c) . Similar decreases were also observed in a second glioblastoma cell line A172 (42 and 45% decreases using siPKCiA and siPKCiB, respectively; Supplementary Figures S1B and C).
To assess the effects of PKCi on the overall invasive ability of glioblastoma cells (that is, their motility as well as ability to penetrate through tissue barriers), the effects of PKCi depletion on the migration of glioblastoma cells through Transwell chamber membranes coated with Matrigel were also assayed. Depletion of PKCi also caused a significant decrease in the ability of glioblastoma cells to pass through Matrigel-coated membranes (for U87MG cells, 55 and 59% decreases with siPKCiA and siPKCiB, respectively (Figures 1b  and d Figures S1B and D) ). Comparing the data for motility alone (that is, no Matrigel) and overall invasion (that is, with Matrigel), the reductions in the numbers of cell crossing the Transwell chamber membranes are higher in the presence of Matrigel, but the overall differences between the values with and without Matrigel are not large. This shows that PKCi primarily increases invasion by promoting cell motility, but may also increase the ability of glioblastoma cells to break down surrounding extracellular matrix as well. Consistent with a role for PKCi in cell motility, PKCi also regulated actin stress fiber formation in glioblastoma cells ( Figure 1e ).
RhoB expression is repressed in glioblastoma
Microarray expression analysis was previously performed on U87MG cells that were depleted of PKCi by RNAi (Baldwin et al., 2006) . Supplementary Table S1 shows microarray analysis data for RhoB mRNA expression. Depletion of PKCi alone caused eightfold increase in the levels of RhoB mRNA expression. PKCi had no effect on RhoA or RhoC mRNA levels (data not shown). Quantitative RT-PCR showed that PKCi depletion increased RhoB mRNA levels 4.4±0.8-fold (mean of three separate determinations ± s.d.). This confirms the regulation of RhoB mRNA levels by PKCi, but indicates that the magnitude of the change was overestimated in the microarray analysis.
Depletion of PKCi also caused a two-to fourfold increase in RhoB protein expression in U87MG ( Figure 2a ) and A172 cells (Supplementary Figure S2A) . Expression of RhoB was also assessed in normal human astrocytes (NHA) and glioblastoma cell lines (U87MG, A172, U118). RhoB protein expression was repressed in each of the glioblastoma cell lines compared to the NHA (Figure 2b ). In contrast, levels of PKCi were higher in each of the three glioblastoma cell lines compared to NHA.
Inhibition of PKCi activity enhances RhoB expression
The effects of pharmacological inhibition of PKCi on RhoB expression were assessed using a myristoylated atypical PKC pseudosubstrate peptide (Kanzaki et al., 2004) . For these experiments, PKCi activity was monitored with an antibody that recognizes Thr555-phosphorylated PKCi. This phosphorylation site lies in the turn motif that is conserved across the AGC family of kinases to which PKCi belongs; phosphorylation at this site stabilizes an active conformation (Messerschmidt et al., 2005) and is likely due to autophosphorylation that follows phosphorylation by PDK1 on the activation loop (Newton, 2003) . Treatment of glioblastoma cells with inhibitor caused a dose-dependent decrease in PKCi phosphorylation and a corresponding increase in RhoB levels (Figure 2c and Supplementary Figure S2B) . To examine the role of PI3K in the activation of PKCi and the repression of RhoB in human glioblastoma cells, LY294002 was used to pharmacologically inhibit PI3K. This also caused a decrease in PKCi phosphorylation and an increase in RhoB levels (Figure 3a ). In addition, PTEN was reintroduced into U87MG cells (both U87MG and A172 cells do not express PTEN due to mutational inactivation (Ishii et al., 1999) ) using retroviral transduction. Restoration of PTEN decreased levels of PKCi phosphorylation; this was also accompanied by an increase in RhoB expression levels (Figure 3b ).
To determine whether the effects of PKCi on RhoB involved p38MAP kinase, U87MG cells depleted of PKCi were treated with the p38MAP kinase inhibitor SKF86002, which is active against all four p38MAP kinase members (Losa et al., 2003) . SKF86002 had no effect on RhoB levels in U87MG cells, and did not affect the increase in RhoB with PKCi depletion (Figures 3c  and d) . Inhibition of ERK also did not affect RhoB levels (data not shown).
RhoB inhibits glioblastoma cell motility and invasiveness
To examine the effect of RhoB on glioblastoma cell motility, we made U87MG and A172 cells that constitutively express high levels of RhoB (Figures 5a and b, top panels). These cells showed significant reductions in motility in both scratch-wound ( Figure 4a and Supplementary Figure S3A Figures S3B and C) ). Glioblastoma cells constitutively expressing high levels of RhoB also had significantly reduced invasion through Matrigel (71% decrease in U87MG cells (Figures b and d) ; 54% decrease in A172 cells (Supplementary Figures S3B and D) ). U87MG and A172 cells constitutively expressing high levels of RhoB also showed a reduction in growth rate compared to empty vector containing control cells ( Supplementary  Figures S3E and F) . The Transwell motility and invasion assays described above are not affected by these differences in proliferation rates, as no significant difference in proliferation is observed at 24 h. Consistent with the previously described ability of Rho proteins to induce actin stress fiber formation (Wheeler and Ridley, 2004) , overexpression of RhoB in glioblastoma cells also caused an increase in actin stress fibers when compared to control cells (Figure 4e ).
RhoB expression inhibits activation of PKCi
Previously, it has been reported that RhoB has the ability to negatively regulate PI3K pathway signaling in some cell types (Liu and Prendergast, 2000) . To evaluate the effect of RhoB expression on PKCi activity, glioblastoma cells stably expressing RhoB from a constitutive promoter were examined for the phosphorylation of PKCi at Thr555. RhoB overexpression in glioblastoma cell lines resulted in a reduced phosphorylation of PKCi at Thr555 (Figures 5a and b) , showing that RhoB can regulate the activity of this enzyme. Consistent with previous reports we also observed a decrease in PKB/Akt phosphorylation (Figures 5a and  b) , indicating that RhoB regulation of these activities occurs upstream of these enzymes.
Discussion
Glioblastoma multiforme is almost invariably a fatal disease, primarily because of its invasive nature. Here, we show that PKCi has a role in promoting glioblastoma cell invasion. There is a precedent from the previous studies showing that atypical protein kinase C is involved in the polarized migration of cultured astrocytes (Etienne-Manneville et al., 2005) and that PKCi is involved in the nicotine-activated migration and invasion of H1299 human non-small cell lung cancer cells (Xu and Deng, 2006) . The actin cytoskeleton is a dynamic element within cells that undergoes changes that are essential to cell motility (Lambrechts et al., 2004) . PKCi depletion resulted in the formation of long actin stress fibers; similar changes in stress fibers were described by Soloff et al. (2004) , in PKCi knockout mouse embryonic fibroblasts) and other studies have also implicated the atypical protein kinase C family in stress fiber loss (Uberall et al., 1999; Coghlan et al., 2000) .
Our previous microarray analysis of PKCi-mediated gene expression identified RhoB as a gene that was negatively regulated by PKCi. RhoB expression is known to be induced by a number of cellular stresses (Fritz et al., 1995) . The stress-inducible fraction of RhoB expression is, in some cases, dependent on p38 MAP kinase (Gerhard et al., 2005) . RhoB levels are also controlled by a second mechanism that involves the PI3K pathway (Jiang et al., 2004) . We show here that PKCi is a downstream mediator in this pathway in glioblastoma cells, with both pharmacological inhibition of PKCi and depletion of PKCi using RNAi pointing to a role for PKCi in repressing RhoB expression. Inhibition of PI3K, either pharmacologically or with transduced PTEN, also caused an increase in RhoB levels that was similar in magnitude to that seen with PKCi inhibition. These data indicate that aberrant activation of the PI3K pathway in glioblastoma represses RhoB expression primarily via activation of PKCi. Previously, it has been reported that in NIH3T3 mouse fibroblasts and human pancreatic cancer cells, PKB/Akt represses RhoB expression downstream of PI3K activation (Jiang et al., 2004) . Inhibition of PKCi with myristoylated pseudosubstrate peptide increased RhoB levels without any effect on PKB/Akt phosphorylation (Figure 2c) , showing that the role of PKCi in RhoB regulation is independent of PKB/Akt in glioblastoma cells. Recent study suggests that PKCi and PKB/Akt share some similar downstream functions, for example, both enzymes can phosphorylate the anti-apoptotic protein Bad . It is conceivable that different tissues may rely more on one enzyme than on other for RhoB regulation. PKCi has been shown to be expressed at higher levels in brain tissues compared to other tissues (Selbie et al., 1993) . Therefore, in brain tissue and potentially brain tumors, cells may preferentially signal through PKCi as the dominant downstream PI3K effector. In addition, the tissue-specific expression of adaptor or anchoring proteins may play a role in the dependence of one enzyme on another in particular cell types. It is also possible that the dominant-negative PKB/Akt used in the previous study functions, in part, as a pseudosubstrate inhibitor of PDK1, which could potentially result in the inhibition of multiple kinases downstream from PDK1 including PKCi. and PKCi following a 1 h pretreatment with SKF86002 (10 mM) and 1 h anisomycin (10 mM) treatment, showing that SKF86002 effectively blocks p38 MAP kinase activation in U87MG cells. All inhibitor treatments were carried out on cells in serum-containing media.
We found that RhoB levels were higher in NHA levels compared to those in three different glioblastoma cell lines. This is consistent with the previous observation that levels of RhoB are repressed in tissue samples from high-grade glioblastomas compared to those from a lower grade and normal brain (Forget et al., 2002) . PKCi protein levels were higher in the glioblastoma lines. Increased levels of PKCi protein have been reported in lung and ovarian cancer because of increased copy number of the PKCi gene (Regala et al., 2005a; Zhang et al., 2006) ; additionally increased levels of PKCi protein have been observed in leukemia cell lines, where there is an increase in transcription of the PKCi gene (Gustafson et al., 2004) . We do not currently know if one of these mechanisms is also responsible for the increased PKCi levels in glioblastoma.
To bypass the repression of RhoB by PKCi, we transduced glioblastoma cells with a cDNA that expressed RhoB from a constitutive promoter. As with PKCi depletion, these cells showed reduced motility and invasion along with increased numbers of actin stress fibers. Therefore, it appears that the effects of PKCi on both motility and actin dynamics are because of its ability to repress RhoB expression.
It has been reported that RhoB is able to suppress activation of PKB/Akt in human breast pancreatic cancer cells, but not fibroblasts (Liu and Prendergast, 2000) . As this suggests a role for RhoB in regulating PI 3-kinase pathway signaling, we determined whether RhoB constitutive expression also suppressed the activity of PKCi. This was the case, as RhoB repressed phosphorylation of PKCi on Thr555 in two different human glioblastoma cell lines. The exact mechanism of how RhoB accomplishes this remains unclear, but as we also see repression of PKB/Akt phosphorylation it is likely to occur at a point upstream of these kinases. RhoB has been shown to recruit PDK1 to endosomes (Flynn et al., 2000) ; one possibility is that PDK1 in endosomes is unable to activate PKCi and PKB/Akt effectively. Secondly, the regulation could be at the receptor level as it has been suggested that RhoB may control endosomal targeting and trafficking of the EGFR (Gampel et al., 1999) . Our data show that PKCi and RhoB are mutually antagonistic, with PKCi repressing RhoB mRNA levels and RhoB repressing PKCi activation (Figures 5c and d) . The kinetic consequence of mutually antagonistic networks is that analog signals are converted into a binary output. This has been demonstrated both theoretically and experimentally with the construction of an artificial 'toggle' switch in bacteria containing two repressible promoters arranged in a mutually inhibitory network (Gardner et al., 2000) . The mutual antagonism between PKCi and RhoB may, therefore, provide the basis for a 'switch', such that a cell is either motile or non-motile without an intermediate state. Our data show only a partial reduction in cell motility with PKCi depletion or constitutive RhoB expression; analysis of individual cells using live cell imaging would determine whether this represents a change in the proportion of motile to non-motile cells (consistent with a 'switch' model) or a decrease in the rate of movement of individual cells.
In summary, our data define a role for PKCi in glioblastoma cell motility and invasion. Mechanistically, we show that PKCi is activated in glioblastoma because of aberrant upstream PI3K signaling and that repression of RhoB is key downstream event in PKCi signaling leading to enhanced cell motility. The repression of RhoB expression by PKCi also provides a mechanism for (1) the previously reported downregulation of RhoB in human glioblastoma, and (2) the PKCi-mediated loss of actin stress fibers that has been observed in a number of different cell types. These results and our previous study (Baldwin et al., 2006) suggest that PKCi should be evaluated further as a potential drug target for glioblastoma therapy. monoclonal were from BD Biosciences (Mississauga, ON, Canada). Phospho-Akt/PKB, Akt/PKB and PDK1 rabbit polyclonal antibodies were from Cell Signaling Technology (Beverly, MA, USA). Pan Erk monoclonal antibody was from Transduction Laboratories (Lexington, KY, USA). LY294002, SKF86002 and the atypical PKC inhibitor peptide were from Sigma (Oakville, ON, Canada), Calbiochem (San Diego, CA, USA) and Biosource (Camarillo, CA, USA), respectively.
Materials and methods
Chemicals and antibodies
Cell lines NHA were purchased from Cambrex Bioscience (Walkersville, MD, USA) and were maintained in astrocyte growth media (Lonza Group Ltd, Basel, Switzerland) supplemented as recommended by the manufacturer. The human glioblastoma cell line U87MG was obtained from Dr W Cavenee (Ludwig Institute for Cancer Research, La Jolla, CA, USA). A172 and U118 cells were from the American Type Culture Collection. Cells were cultured as described previously (Lavictoire et al., 2003) .
RNA transfections
Depletion of PKCi using RNAi was carried out as described previously (Baldwin et al., 2006) . The control RNA duplex had the sense RNA sequence UAGCGACUAAACACAUCAA (siControl, Dharmacon RNA Technologies Inc. (Lafayette, CO, USA)).
Western blot analysis
Western blotting was performed as described previously (Baldwin et al., 2006) . After electrophoretic transfer from the gel, blots were stained with Amido Black to confirm that equal sample loading and transfer was achieved.
Construction of PTEN and RhoB expression vector
Full-length cDNA for human PTEN was obtained from the American Type Culture Collection. PTEN cDNA was cloned into the retroviral vector pLPCX (Clontech, Palo Alto, CA, USA). Retroviral MSCVpac and MSCVpac-RhoB vectors were a generous gift from Dr G Prendergast (Lankenau Institute for Medical Research, Wynnewood, PA, USA). Retrovirus containing PTEN or RhoB cDNA was made as described previously (Lavictoire et al., 2003) . Cells were grown in media containing puromycin (1 mg ml À1 ) to select for transductants.
Cell counts
Live cell number was determined using a Vi-Cell XR cell viability analyser (Beckman Coulter Canada Inc., Mississauga, ON, Canada).
Cell motility and invasion assays Scratch-wound assays were carried out as described (Sang et al., 2007) . For Transwell chamber assays, BD Biocoat Matrigel invasion chambers (BD Biosciences) were used. Details of the procedures are shown in Supplementary Figure S1 .
Statistical analysis
All results were expressed as the mean ± s.d. Statistical analysis was performed using the two-tailed Student's t-test, and Po0.05 was considered statistically significant.
